Skip to content

Exploration of Intervention Targets for Hypertension and Its Complications

Exploration of Intervention Targets for Hypertension and Its Complications

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118802
Enrollment
Unknown
Registered
2026-02-11
Start date
2026-02-15
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, with or without complications such as hypertensive heart disease, coronary heart disease, and heart failure.

Interventions

Hypertension (HTN) Group:None
Control Group:None
Hypertension with Ischemic Heart Disease (HTN + IHD) Group:None
Hypertensive Heart Disease (HHD) Group:None

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion Criteria for the Control Group (all must be met): (1) Age >=18 and =18 and <=80 years, regardless of gender; (2) A clear diagnosis of primary hypertension, meeting the criteria of the Chinese Guidelines for the Prevention and Treatment of Hypertension or the ESC/ESH hypertension guidelines; (3) Complete clinical case data; (4) Availability of discarded blood samples (plasma and/or serum) without hemolysis or contamination.

Exclusion criteria

Exclusion criteria: 1.Control Group: (1) History of definite acute infection, malignancy, or systemic inflammatory disease; (2) Diagnosed cardiomyopathy; (3) Severe valvular heart disease; (4) Diagnosed secondary hypertension; (5) Severe liver dysfunction (ALT or AST >= 3 times the upper limit of normal) or confirmed active hepatitis or decompensated cirrhosis; (6) Moderate to severe renal insufficiency (estimated eGFR = 3 times the upper limit of normal) or confirmed active hepatitis or decompensated cirrhosis; (6) Moderate to severe renal insufficiency (estimated eGFR < 60 ml/min/1.73 m^2); (7) Severe endocrine disorders, including but not limited to uncontrolled hyperthyroidism, hypothyroidism, or diabetes; (8) Any other condition deemed unsuitable for inclusion in this study by the investigator.

Design outcomes

Primary

MeasureTime frame
Transcriptional and translational expression levels of RIP3, ZBP1, SULF1, and other genes;Blood routine and biochemical indicators;Echocardiography, chest CT, abdominal and urinary system color Doppler ultrasound;

Countries

China

Contacts

Public ContactHuang Zhengrong

The First Affiliated Hospital of Xiamen University

huangzhengrong@xmu.edu.cn+86 592 2137111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026